Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to ...

On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

On this week's Business of Biotech episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's ...

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, write experts at Faegre Drinker and Aurobindo Pharma USA.

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

Failure to comply with clinical trial disclosure regulations poses risks that extend far beyond potential fines or reputational damage for sponsors. In the context of mergers and acquisitions (M&A), ...